Analyst Predicts Moderna Stock Could Soar to $214, Cites Promising New Vaccines

Monday, 1 April 2024, 19:52
Analysts foresee Moderna's stock price potentially doubling with new vaccines set to receive FDA approval, including a vaccine for the respiratory syncytial virus. Despite its success with the COVID-19 vaccine, Moderna's oncology and infectious disease pipeline could drive significant revenue growth.
https://store.livarava.com/ef36b173-f061-11ee-8928-87cc5c87fb08.jpg
Analyst Predicts Moderna Stock Could Soar to $214, Cites Promising New Vaccines

Analyst Predicts Market Opportunity

One analyst believes Moderna's stock could see substantial growth, reaching $214, as the company enters a new phase with potential FDA-approved vaccines.

Recent Clinical Trials

  • Moderna's investigational vaccines against viral threats like EBV and norovirus show promising results, indicating future revenue potential.

This fresh technology could lead to significant share price appreciation and long-term success for investors considering Moderna.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe